Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient monotonicity, with median survivals of 52.0, 36.2, 29.9, and 14.1 months respectively. However, predicted survivals systematically underestimated observed survivals (R2: 0.667). A recalibration was adopted maintaining fixed the prognostic index and modifying the baseline survival function. This resulted in an almost perfect calibration (R2: 0.995) in all the four risk categories. Cox regressions showed that aetiology and macrovascular invasion, included in the Pre-TACE-Predict model, had no prognostic impact in the present study population, and that coefficients for tumour size and multiplicity were overestimated. The c-index was similar to that of the m-HAP-III, but higher than those of HAP, m-HAP-II and the six-and-twelve models. Conclusions The recalibration of Pre-TACE-Predict model improved the estimation of survival probabilities of HCC patients treated with TACE. The highest discriminatory ability of the Pre-TACE-model in comparison to other available models, together with risk stratification and recalibration, makes it the best prognostic tool currently available for these patients.

Cucchetti, A., Giannini, E.G., Mosconi, C., Plaz Torres, M.C., Pieri, G., Farinati, F., et al. (2021). Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma. LIVER CANCER INTERNATIONAL, 2(2), 45-53 [10.1002/lci2.33].

Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

Cucchetti, Alessandro;Mosconi, Cristina;Sansone, Vito;Zoli, Marco;Azzaroli, Francesco;Trevisani, Franco;Biselli, Maurizio;Caraceni, Paolo;Gramenzi, Annagiulia;Reggidori, Nicola;Santi, Valentina;Stefanini, Benedetta;Granito, Alessandro;Piscaglia, Fabio;Tovoli, Francesco;Dajti, Elton;Marasco, Giovanni;Ravaioli, Federico;Golfieri, Rita;Facciorusso, Antonio;Napoli, Lucia;Bevilacqua, Vittoria;Berardinelli, Dante;Borghi, Alberto;Conti, Fabio;Dall'Aglio, Anna Chiara;Ercolani, Giorgio;Di Bonaventura, Chiara;Gitto, Stefano;
2021

Abstract

Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient monotonicity, with median survivals of 52.0, 36.2, 29.9, and 14.1 months respectively. However, predicted survivals systematically underestimated observed survivals (R2: 0.667). A recalibration was adopted maintaining fixed the prognostic index and modifying the baseline survival function. This resulted in an almost perfect calibration (R2: 0.995) in all the four risk categories. Cox regressions showed that aetiology and macrovascular invasion, included in the Pre-TACE-Predict model, had no prognostic impact in the present study population, and that coefficients for tumour size and multiplicity were overestimated. The c-index was similar to that of the m-HAP-III, but higher than those of HAP, m-HAP-II and the six-and-twelve models. Conclusions The recalibration of Pre-TACE-Predict model improved the estimation of survival probabilities of HCC patients treated with TACE. The highest discriminatory ability of the Pre-TACE-model in comparison to other available models, together with risk stratification and recalibration, makes it the best prognostic tool currently available for these patients.
2021
Cucchetti, A., Giannini, E.G., Mosconi, C., Plaz Torres, M.C., Pieri, G., Farinati, F., et al. (2021). Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma. LIVER CANCER INTERNATIONAL, 2(2), 45-53 [10.1002/lci2.33].
Cucchetti, Alessandro; Giannini, Edoardo G.; Mosconi, Cristina; Plaz Torres, Maria Corina; Pieri, Giulia; Farinati, Fabio; Rapaccini, Gian Ludovico; D...espandi
File in questo prodotto:
File Dimensione Formato  
30.Cucchetti - Recalibrating survival prediction.pdf

accesso aperto

Descrizione: Articolo in rivista
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 789.33 kB
Formato Adobe PDF
789.33 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/854438
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact